GEO DataSets

Analysis of pre and post (3 wk) tumor core biopsies of postmenopausal women with ER+, HER2- breast cancer (BC) in neoadjuvant trial of anastrozole and fulvestrant with/without gefitinib. Results provide insight into mechanisms of resistance and inhibition of hormone receptors targeted in BC therapy.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 agent, 4 disease state, 2 protocol, 2 specimen sets

Platform:

GPL570

Series:

GSE33658

22 Samples

Download data: CEL

(Submitter supplied) Endocrine therapy in patients with breast cancer can be limited by the problem of resistance. Preclinical studies suggest that complete blockade of the estrogen receptor (ER) combined with inhibition of the epidermal growth factor receptor (EGFR) can overcome endocrine resistance. We tested this hypothesis in a phase II neoadjuvant trial of anastrozole and fulvestrant combined with gefitinib in postmenopausal women with newly diagnosed ER-positive breast cancer. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4093

Platform:

GPL570

22 Samples

Download data: CEL

(Submitter supplied) Agilent gene expression arrays were used to compare proliferation signatures between pre-treatment and 2-4 weeks post treatment samples from Z1031B patients.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6480

218 Samples

Download data: TXT

(Submitter supplied) Agilent gene expression arrays were used for intrinsic subtyping and to measure changes after anastrozole (C1D1) and after combination of anastrazole and palbociclib (C1D15).

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6480

118 Samples

Download data: TXT

(Submitter supplied) PAM50 intrinsic subtype classification (Parker JS, Mullins M, Cheang MCU, et al: Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol 27:1160-1167, 2009) was used for the Z1031 patient cohort. However, to account for potential technical biases such as differences in platforms and laboratory protocols between the Z1031 data set and the PAM50 training set2, we normalized the Z1301 data set before applying the PAM50 algorithm. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6480

40 Samples

Download data: TXT

(Submitter supplied) Aromatase inhibitors are first-line postmenopausal agents for estrogen receptor alpha (ERa)-positive breast cancer. However, there is considerable response heterogeneity and women frequently relapse. Estrogen deprivation does not completely arrest ERa activity, and transactivation of the unliganded receptor may continue through cross-talk with growth factor pathways. In contrast with aromatase inhibitors, the selective ER downregulator fulvestrant also abrogates ligand-independent ERa activity. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6884

76 Samples

Download data: TXT

(Submitter supplied) gene expression analysis ussing microarray analysis of a subset of primary tumors collected from patients that participated in the CONFIRM phase III study, which randomized post menopausal patients with ER+ metastatic breast cancer to fulvestrant 500mg and fulvestrant 250mg.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL17586

113 Samples

Download data: CEL

(Submitter supplied) Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

96 Samples

Download data: CEL

(Submitter supplied) The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological activity of fulvestrant 500 mg vs 250 mg in the neoadjuvant setting. In this multi-centre phase II study, post-menopausal women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumours were randomised to receive neoadjuvant treatment with either dose of fulvestrant for 16 weeks before surgery. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

42 Samples

Download data: CEL

(Submitter supplied) Introduction: Peri-operative window trials, using molecular biomarkers as surrogate endpoints for treatment response, offer investigators a uniqueopportunity to obtain intact tumor samples at 2 different time-points and thus evaluate potential biomarkers over a short period of time. Here we report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected after a 10-day exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared to untreated controls. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL11417

38 Samples

Download data

(Submitter supplied) Background: AZD4547 is a potent and selective inhibitor of FGFR-1, 2 and 3 receptor tyrosine kinases. Phase 1 studies both in Europe and Japan have shown that the compound is well tolerated and shows activity in patients with solid tumours. Here, we hypothesised that AZD4547 could reverse resistance to AIs such as anastrozole and letrozole. Methods: After a safety run-in study in which 6 patients had PK and safety assessments on combined AI plus AZD4547, we recruited 52 eligible patients with metastatic breast cancer who had progressed on treatment with anastrozole or letrozole. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

22 Samples

Download data: CSV